The Effect of Timing of Intravenous Paracetamol Administration on Post-surgical Pain

Sponsor
Soroka University Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT03221998
Collaborator
(none)
126
2
32

Study Details

Study Description

Brief Summary

This study is designed as a population-based prospective randomized cohort study. A prospective cohort of patients admitted to laparoscopic sleeve gastrectomy due to morbid obesity

Condition or Disease Intervention/Treatment Phase
  • Drug: IV paracetamol
  • Drug: IV saline (NaCl 0.9 %)
Early Phase 1

Detailed Description

All adult consecutive patients admitted to surgical departments for laparoscopic sleeve gastrectomy will be enrolled prospectively.

For the purposes of the current study we want to determine how much paracetamol (acetaminophen) can reduce the cytokines levels in these patients

The study enrollment period is planned to be a year. The follow-up period for each patient will be until discharge from the hospital.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
126 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This study is designed as a population-based prospective randomized cohort study. A prospective cohort of patients admitted to laparoscopic sleeve gastrectomy due to morbid obesityThis study is designed as a population-based prospective randomized cohort study. A prospective cohort of patients admitted to laparoscopic sleeve gastrectomy due to morbid obesity
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect of Timing of Intravenous Paracetamol Administration on Post-surgical Pain and Cytokines Levels Following Laparoscopic Sleeve Gastrectomy
Anticipated Study Start Date :
Jul 1, 2017
Anticipated Primary Completion Date :
Mar 1, 2019
Anticipated Study Completion Date :
Mar 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: IV paracetamol

Patients in the first group will receive in the operating room before surgery 1 gram (100 ml) of intravenous paracetamol ( IV paracetamol) for 15 minutes intraoperative

Drug: IV paracetamol
100 gram paracetamol infusion for moderate pain management
Other Names:
  • Perfalgan infusion (paracetamol)
  • Placebo Comparator: IV saline (NaCl 0.9 %)

    Patients in the second group will receive 100 mL NACL 0.9% (IV NaCl 0.9 %)intraoperative

    Drug: IV saline (NaCl 0.9 %)
    100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
    Other Names:
  • Normal Saline
  • Outcome Measures

    Primary Outcome Measures

    1. measuring of Visual Analogue pain Scale, [up to 48 hours after surgery]

      Visual Analogue pain Scale to determine patient level of pain , for establish the correct timing of paracetamol administration

    2. measuring of Cytokine levels [up to 48 hours after surgery]

      measuring of Cytokine levels in comparison of timing of paracetamol administration , as a predictor for inflammatory mediators released in response to noxious stimuli

    Secondary Outcome Measures

    1. Total consumption of opiates after surgery [up to 72 hours after surgery]

      post - operative opioid consumption in manner of dosage and frequency in ward

    2. Respiratory post-operative complication while in ward [up to 72 hours after surgery]

      Respiratory complication (need of respiratory support, need of intensive care unit hospitalization)

    3. septic post-operative complication while in ward [up to 72 hours after surgery]

      development of fever above 38° C

    4. Cardiovascular post-operative complication while in ward [up to 72 hours after surgery]

      Cardiovascular complication (hemodynamic instability, inotropic support )

    5. Gastrointestinal post-operative complication while in ward [up to 72 hours after surgery]

      Gastrointestinal complaints as nausea and vomiting, need to use antiemetic drug

    6. urinary trak post-operative complication while in ward [up to 72 hours after surgery]

      Incidence of urinary retention and need for catheterization

    7. post-operative pruritus while in ward [up to 72 hours after surgery]

      Pruritus

    8. post-operative hospitalization [up to one week after surgery]

      length of hospital stay by number of days

    9. Respiratory post-operative complication while recovering in post anesthesia care unit [up to 5 hours after surgery]

      Respiratory complication need of respiratory support, need of intensive care unit hospitalization)

    10. septic post-operative complication while recovering in post anesthesia care unit [up to 5 hours after surgery]

      Development of fever above 38° C

    11. Cardiovascular post-operative complication while recovering in post anesthesia care unit [up to 5 hours after surgery]

      Cardiovascular complication (hemodynamic instability, inotropic support )

    12. Gastrointestinal post-operative complication while recovering in post anesthesia care unit [up to 5 hours after surgery]

      Gastrointestinal complication as nausea and vomiting, need to use antiemetic drugs

    13. urinary retention post-operative complication while recovering in post anesthesia care unit [up to 5 hours after surgery]

      incience of urinary retention and need for catheterization

    14. post-operative pruritus while recovering in post anesthesia care unit [up to 5 hours after surgery]

      Pruritus

    15. post-operative stay in post anesthesia care unit [up to 5 hours after surgery]

      length of post anesthesia care unit stay by number of hours

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 100 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age ≥18 years

    • Patients admitted for laparoscopic sleeve gastrectomy

    • Elective surgery

    • BMI > 40

    • American Society of Anesthesiology Classification: 1-2

    Exclusion Criteria:
    • Patients' refusal to participate in the study

    • Patients unable to give an informed consent

    • Pregnancy

    • Emergency surgery

    • Patient with known allergy to paracetamol

    • Patient with hepatic failure

    • international normalized ratio >1.7

    • Albumin<3.5g/Dl

    • Bilirubin >2mg/dL

    • Patient with fever > 37.5 ° C

    • Patient with hemoglobin < 8

    • Patients chronically treated with steroids or steroid-treated patients over a month in the year preceding surgery.

    Drug addict

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Soroka University Medical Center

    Investigators

    • Study Director: Michael Semionov, MD, Soroka University Medical Center-Department of Anesthesiology
    • Study Chair: Alexander Zlotnic, PhdMD, Soroka University Medical Center-Department of Anesthesiology
    • Principal Investigator: Yair Binyamin, MD, Soroka University Medical Center-Department of Anesthesiology
    • Principal Investigator: Yair Yaish Reina, MD, Soroka University Medical Center-Department of Anesthesiology

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Yair Binyamin MD, principal lnvestigator, Soroka University Medical Center
    ClinicalTrials.gov Identifier:
    NCT03221998
    Other Study ID Numbers:
    • sor17ybyrctil
    First Posted:
    Jul 19, 2017
    Last Update Posted:
    Jul 25, 2017
    Last Verified:
    Jul 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Yair Binyamin MD, principal lnvestigator, Soroka University Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 25, 2017